Post-Traumatic Stress Disorder (PTSD)

The short version

●PTSD follows exposure to actual or threatened death, serious injury, or sexual violence and is defined by four symptom clusters: intrusion (flashbacks, nightmares), avoidance, negative changes in mood and cognition, and hyperarousal — lasting more than one month.
●First-line treatment is trauma-focused psychotherapy (prolonged exposure, CPT, EMDR); SSRIs (sertraline, paroxetine) are FDA-approved but generally less effective than trauma-focused therapy.
●A substantial minority do not respond to first-line care, and PTSD is frequently comorbid with depression, substance use, and chronic pain.
●A randomized controlled trial (Feder 2014, JAMA Psychiatry) found a single ketamine infusion produced rapid, significant reduction in core PTSD symptoms versus active control — the first controlled evidence for rapid-acting pharmacotherapy in PTSD.
●Ketamine enhances glutamatergic plasticity and fear-extinction processes, which is mechanistically relevant to how traumatic memories are reconsolidated.
●Ketamine is not first-line; it is considered for treatment-resistant PTSD, especially with comorbid treatment-resistant depression, and works best paired with trauma-focused therapy.

Clinical definition

PTSD develops after exposure to actual or threatened death, serious injury, or sexual violence — directly experienced, witnessed, learned about (a close other), or through repeated occupational exposure (e.g., first responders). DSM-5 requires symptoms from four clusters persisting more than one month: (1) intrusion — recurrent involuntary memories, nightmares, dissociative flashbacks, intense distress at reminders; (2) avoidance of trauma-related thoughts, feelings, or external reminders; (3) negative alterations in cognition and mood — persistent negative beliefs, distorted blame, detachment, anhedonia, inability to feel positive emotion; (4) marked alterations in arousal and reactivity — irritability, recklessness, hypervigilance, exaggerated startle, and concentration and sleep problems. A dissociative subtype (with depersonalization or derealization) is specified. Complex PTSD (ICD-11) adds disturbances in self-organization following prolonged or repeated trauma.

How it differs from related conditions

vs. Acute stress disorder

Same symptom domains but within the first 3 days to 1 month after trauma; PTSD is diagnosed when symptoms persist beyond one month.

vs. Complex PTSD

Follows prolonged or repeated interpersonal trauma and adds pervasive affect dysregulation, negative self-concept, and relationship disturbance; treatment is typically longer and phase-based.

vs. Major depressive disorder

Shares anhedonia, sleep disturbance, and negative cognition, and frequently co-occurs; PTSD is distinguished by the trauma anchor, intrusion symptoms, and hyperarousal.

vs. Panic disorder / GAD

Anxiety disorders without the defining traumatic event, intrusion cluster, or avoidance of trauma reminders.

First-line treatments

Trauma-focused psychotherapy (PE, CPT, EMDR)

Prolonged exposure, cognitive processing therapy, and EMDR have the strongest evidence and are first-line across guidelines; effect sizes exceed medication for most patients.

SSRIs (sertraline, paroxetine)

The two FDA-approved medications for PTSD; modest efficacy, useful when trauma-focused therapy is unavailable or declined, or for comorbid depression.

SNRIs (venlafaxine)

Off-label but with supportive trial evidence; an alternative to SSRIs.

Prazosin for nightmares

An alpha-1 blocker that specifically targets trauma-related nightmares and sleep disruption; adjunctive, not a treatment for the full syndrome.

When standard treatments fail

Treatment-resistant PTSD is inadequate response to adequate trauma-focused therapy and/or SSRI/SNRI trials. The escalation path: ensure a genuine course of trauma-focused therapy was offered (the most evidence-based step, and often the missing one) → optimize or switch SSRI, or move to venlafaxine → add prazosin for nightmares and treat comorbid depression, substance use, and sleep → consider augmentation and, increasingly, rapid-acting or experimental approaches (ketamine; MDMA-assisted therapy is under regulatory review). Comorbidity is the rule, not the exception, and treating co-occurring depression and substance use often unlocks progress on the PTSD itself.

Where ketamine fits

Ketamine has among the most encouraging controlled evidence of any rapid-acting medication for PTSD. In a randomized, double-blind trial (Feder 2014, JAMA Psychiatry), a single ketamine infusion produced a rapid and significant reduction in core PTSD symptoms compared with an active control, and a later repeated-dosing trial extended the signal. Mechanistically, ketamine enhances glutamatergic plasticity and fear-extinction processes, which is relevant to how traumatic memories are reconsolidated. The practical limitations are durability and the need for psychotherapy: ketamine can rapidly reduce hyperarousal, intrusion, and the comorbid depression that frequently accompanies PTSD, but lasting recovery generally requires trauma-focused therapy. The most promising clinical models pair ketamine with concurrent PE, CPT, or EMDR, using the post-session neuroplastic window to make trauma-processing work more tolerable. Ketamine is most appropriate for treatment-resistant PTSD, especially with comorbid treatment-resistant depression.

Where this fits with Tovani

Tovani treats PTSD when it co-occurs with treatment-resistant depression or after adequate first-line care has been tried. Because durable PTSD recovery generally requires trauma-focused therapy, Tovani encourages patients to maintain or establish a relationship with a trauma therapist (PE, CPT, or EMDR) alongside ketamine. The at-home dissociative experience requires extra preparation for trauma patients: the depersonalization or derealization of a session can resemble trauma-related dissociation, so screening, education, and a trusted support person are emphasized, and patients with a history of pathological dissociation may need slower, more carefully titrated protocols. Eligibility screening captures trauma history, dissociative symptoms, and comorbidity.

Check eligibility The science behind ketamine

Frequently asked

Does ketamine erase traumatic memories?

No. Ketamine does not delete memories. It appears to act on the brain's fear-extinction and memory-reconsolidation systems, which may make traumatic memories less overwhelming to process — but that processing still happens through trauma-focused therapy. Ketamine can reduce the hyperarousal and depression that make therapy feel impossible.

Is ketamine better than SSRIs for PTSD?

They do different things. SSRIs are FDA-approved but modest and slow; ketamine works rapidly and has encouraging controlled evidence, but its effects can be short-lived without follow-up therapy. Neither replaces trauma-focused psychotherapy, which remains the most effective treatment.

I have PTSD and the dissociation worries me — is ketamine safe?

It is an important conversation. A ketamine session produces a dissociative state that can resemble trauma-related dissociation, so trauma patients get extra preparation, a trusted support person, and sometimes slower dosing. For some, the experience is processed as meaningful; for those with a history of pathological dissociation, careful screening determines whether and how to proceed.

Should I keep seeing my trauma therapist if I start ketamine?

Yes — ideally. The best outcomes come from pairing ketamine with trauma-focused therapy (PE, CPT, or EMDR). The medication can open a window where trauma-processing work is more tolerable; the therapy is what makes the change last.

References

Feder A et al. 2014, JAMA Psychiatry — Randomized controlled trial; a single intravenous ketamine infusion produced rapid, significant reduction in chronic PTSD symptoms versus an active (midazolam) control. (PMID 24740528)
Sippel LM et al. 2024, American Journal of Psychiatry — Review of novel pharmacologic and other somatic treatment approaches for PTSD, including ketamine and the evidence for trauma-focused therapies. (PMID 39616450)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression — the comorbidity most relevant to PTSD — with 64% response within 24 hours. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 30, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.